• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

工程间充质干细胞治疗卵巢早衰：克服挑战和创新治疗策略。

Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies.

机构信息

Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.

Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, China.

出版信息

Theranostics. 2024 Oct 7;14(17):6487-6515. doi: 10.7150/thno.102641. eCollection 2024.

DOI:10.7150/thno.102641
PMID:39479455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11519806/
Abstract

Premature ovarian failure (POF) is a leading cause of infertility in women, causing significant psychological and physical distress. Current therapeutic options are limited, necessitating the exploration of new treatments. Mesenchymal stem cells (MSCs), known for their remarkable homing and regenerative properties, have emerged as a promising intervention for POF. However, their clinical efficacy has been inconsistent. This paper aims to address these challenges by examining the cellular heterogeneity within MSC populations, which is crucial for identifying and selecting specific functional subpopulations for clinical applications. Understanding this heterogeneity can enhance therapeutic efficacy and ensure treatment stability. Additionally, this review comprehensively examines the literature on the effectiveness, safety, and ethical considerations of MSCs for ovarian regeneration, with a focus on preclinical and clinical trials. We also discuss potential strategies involving genetically and tissue-engineered MSCs. By integrating insights from these studies, we propose new directions for the design of targeted MSC treatments for POF and related disorders, potentially improving outcomes, addressing safety concerns, and expanding therapeutic options while ensuring ethical compliance.

摘要

卵巢早衰（POF）是导致女性不孕的主要原因之一，给患者带来了严重的心理和生理困扰。目前的治疗选择有限，因此需要探索新的治疗方法。间充质干细胞（MSCs）因其显著的归巢和再生特性而成为 POF 的一种有前途的干预手段。然而，其临床疗效并不一致。本文旨在通过研究 MSC 群体中的细胞异质性来解决这些挑战，这对于鉴定和选择特定的功能亚群用于临床应用至关重要。了解这种异质性可以提高治疗效果并确保治疗的稳定性。此外，本综述还全面探讨了 MSCs 用于卵巢再生的有效性、安全性和伦理考虑的文献，重点是临床前和临床试验。我们还讨论了涉及基因和组织工程 MSC 的潜在策略。通过整合这些研究的见解，我们为 POF 和相关疾病的 MSC 靶向治疗设计提出了新的方向，有可能改善治疗效果，解决安全性问题，扩大治疗选择，同时确保符合伦理规范。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/ba9f8b443e37/thnov14p6487g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/f7c74fb10df1/thnov14p6487g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/b4c1aa9693f5/thnov14p6487g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/14a66b0cc784/thnov14p6487g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/a779e305de3c/thnov14p6487g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/4f48a2329ba7/thnov14p6487g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/20fcb3a72599/thnov14p6487g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/63a754f2f67a/thnov14p6487g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/ba9f8b443e37/thnov14p6487g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/f7c74fb10df1/thnov14p6487g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/b4c1aa9693f5/thnov14p6487g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/14a66b0cc784/thnov14p6487g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/a779e305de3c/thnov14p6487g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/4f48a2329ba7/thnov14p6487g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/20fcb3a72599/thnov14p6487g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/63a754f2f67a/thnov14p6487g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888a/11519806/ba9f8b443e37/thnov14p6487g008.jpg

相似文献

1
Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies.工程间充质干细胞治疗卵巢早衰：克服挑战和创新治疗策略。
Theranostics. 2024 Oct 7;14(17):6487-6515. doi: 10.7150/thno.102641. eCollection 2024.
2
The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure.人脐带间充质干细胞治疗卵巢早衰的治疗潜力。
Stem Cell Rev Rep. 2023 Apr;19(3):651-666. doi: 10.1007/s12015-022-10493-y. Epub 2022 Dec 15.
3
Effects of single and multiple transplantations of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice.单次和多次移植人脐带间充质干细胞对治疗小鼠卵巢早衰中卵巢功能恢复的影响。
J Ovarian Res. 2021 Sep 15;14(1):119. doi: 10.1186/s13048-021-00871-4.
4
Transplantation of the LRP1 subpopulation of human umbilical cord-derived mesenchymal stem cells improves ovarian function in mice with premature ovarian failure and aged mice.LRP1 亚群人脐带间充质干细胞移植改善卵巢早衰和老年小鼠的卵巢功能。
Stem Cell Res Ther. 2024 Mar 5;15(1):64. doi: 10.1186/s13287-024-03660-0.
5
Dual-Double Stem Cell Ovarian Therapy: A Comprehensive Approach in Regenerative Medicine.双双重干细胞卵巢疗法：再生医学中的综合方法。
Int J Mol Sci. 2024 Dec 25;26(1):69. doi: 10.3390/ijms26010069.
6
Tracking of human embryonic stem cell-derived mesenchymal stem cells in premature ovarian failure model mice.人胚胎干细胞源性间充质干细胞在卵巢早衰模型小鼠中的示踪研究。
Biochem Biophys Res Commun. 2021 Nov 5;577:6-11. doi: 10.1016/j.bbrc.2021.08.063. Epub 2021 Aug 26.
7
Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility.间充质干细胞作为治疗女性不孕症的生物器官
Cells. 2020 Oct 8;9(10):2253. doi: 10.3390/cells9102253.
8
Effects of Low-Intensity Pulsed Ultrasound on the Migration and Homing of Human Amnion-Derived Mesenchymal Stem Cells to Ovaries in Rats With Premature Ovarian Insufficiency.低强度脉冲超声对人羊膜间充质干细胞向卵巢早衰大鼠卵巢迁移和归巢的影响。
Cell Transplant. 2022 Jan-Dec;31:9636897221129171. doi: 10.1177/09636897221129171.
9
Human chorionic plate-derived mesenchymal stem cells transplantation restores ovarian function in a chemotherapy-induced mouse model of premature ovarian failure.人绒毛膜板源间充质干细胞移植恢复化疗诱导的卵巢早衰小鼠模型的卵巢功能。
Stem Cell Res Ther. 2018 Apr 3;9(1):81. doi: 10.1186/s13287-018-0819-z.
10
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) alleviate excessive autophagy of ovarian granular cells through VEGFA/PI3K/AKT/mTOR pathway in premature ovarian failure rat model.人脐带间充质干细胞（hUC-MSCs）通过 VEGFA/PI3K/AKT/mTOR 通路减轻卵巢早衰大鼠模型中卵巢颗粒细胞的过度自噬。
J Ovarian Res. 2023 Sep 30;16(1):198. doi: 10.1186/s13048-023-01278-z.

引用本文的文献

1
Investigation of the Efficacy of Umbilical Cord Mesenchymal Stem Cell and Melatonin Treatment in Premature Ovarian Failure Model.脐带间充质干细胞与褪黑素治疗对卵巢早衰模型疗效的研究
Reprod Sci. 2025 Aug 14. doi: 10.1007/s43032-025-01942-3.
2
Mesenchymal Stem Cells: A Therapeutic Approach in Fertility Restoration in Premature Ovarian Insufficiency.间充质干细胞：一种用于恢复卵巢早衰生育能力的治疗方法。
Stem Cell Rev Rep. 2025 Oct;21(7):2089-2102. doi: 10.1007/s12015-025-10944-2. Epub 2025 Aug 1.
3
Dual-Double Stem Cell Ovarian Therapy: A Comprehensive Approach in Regenerative Medicine.

本文引用的文献

1
Human lung cancer-derived mesenchymal stem cells promote tumor growth and immunosuppression.人肺癌衍生的间充质干细胞促进肿瘤生长和免疫抑制。
Biol Direct. 2024 May 16;19(1):39. doi: 10.1186/s13062-024-00479-w.
2
Efficacy and safety of mesenchymal stem cell therapy for ovarian ageing in a mouse model.间充质干细胞治疗卵巢衰老小鼠模型的疗效和安全性。
Stem Cell Res Ther. 2024 Apr 3;15(1):96. doi: 10.1186/s13287-024-03698-0.
3
Long Non-Coding RNA-Cardiac-Inducing RNA 6 Mediates Repair of Infarcted Hearts by Inducing Mesenchymal Stem Cell Differentiation into Cardiogenic Cells through Cyclin-Dependent Kinase 1.
双双重干细胞卵巢疗法：再生医学中的综合方法。
Int J Mol Sci. 2024 Dec 25;26(1):69. doi: 10.3390/ijms26010069.
长链非编码 RNA-心脏诱导 RNA6 通过细胞周期蛋白依赖性激酶 1 诱导间充质干细胞向成心肌细胞分化来介导梗死心脏的修复。
Int J Mol Sci. 2024 Mar 19;25(6):3466. doi: 10.3390/ijms25063466.
4
The remodeling of ovarian function: targeted delivery strategies for mesenchymal stem cells and their derived extracellular vesicles.卵巢功能重塑：间充质干细胞及其衍生的细胞外囊泡的靶向递送策略。
Stem Cell Res Ther. 2024 Mar 27;15(1):90. doi: 10.1186/s13287-024-03704-5.
5
miR-873-5p Suppression Reinvigorates Aging Mesenchymal Stem Cells and Improves Cardiac Repair after Myocardial Infarction.miR-873-5p抑制可恢复衰老的间充质干细胞活力并改善心肌梗死后的心脏修复。
ACS Pharmacol Transl Sci. 2024 Jan 23;7(3):743-756. doi: 10.1021/acsptsci.3c00293. eCollection 2024 Mar 8.
6
SOD2 promotes the immunosuppressive function of mesenchymal stem cells at the expense of adipocyte differentiation.SOD2 以牺牲脂肪细胞分化为代价，促进间充质干细胞的免疫抑制功能。
Mol Ther. 2024 Apr 3;32(4):1144-1157. doi: 10.1016/j.ymthe.2024.01.031. Epub 2024 Feb 3.
7
The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy.间充质干细胞的异质性：细胞治疗中需要解决的一个重要问题。
Stem Cell Res Ther. 2023 Dec 20;14(1):381. doi: 10.1186/s13287-023-03587-y.
8
Tissue engineering and stem cell-based therapeutic strategies for premature ovarian insufficiency.针对卵巢早衰的组织工程和基于干细胞的治疗策略
Regen Ther. 2023 Nov 25;25:10-23. doi: 10.1016/j.reth.2023.11.007. eCollection 2024 Mar.
9
Increased Hepatocyte Growth Factor Secretion by Placenta-Derived Mesenchymal Stem Cells Improves Ovarian Function in an Ovariectomized Rat Model via Vascular Remodeling by Wnt Signaling Activation.胎盘来源间充质干细胞通过 Wnt 信号激活促进血管重塑增加肝细胞生长因子分泌从而改善卵巢切除大鼠模型的卵巢功能。
Cells. 2023 Nov 25;12(23):2708. doi: 10.3390/cells12232708.
10
Downregulation of ALKBH5 rejuvenates aged human mesenchymal stem cells and enhances their therapeutic efficacy in myocardial infarction.ALKBH5 的下调可恢复衰老的人骨髓间充质干细胞的活力，并增强其在心肌梗死中的治疗效果。
FASEB J. 2023 Dec;37(12):e23294. doi: 10.1096/fj.202301292R.